Table 2.
Past and present drug discovery/development programs targeting heparanase in oncology.
| Company | Compound | Development stage | ClinicalTrials.gov Identifier/Reference |
|---|---|---|---|
| Medigen Biotechnology Corporation (Taiwan) | Muparfostat (PI-88) | Phase III (current) | NCT01402908 |
| Momenta Pharmaceuticals (US) | Necuparanib (M402) | Phase I/II (current) | NCT01621243 |
| Sigma Tau Pomezia (Italy) | Roneparstat (SST0001) | Phase I (current) | NCT01764880 |
| Progen Pharmaceuticals (Aus) | PG545 from PG500 series | Phase I (current) | NCT02042781 |
| Oxford Glycosciences (UK) | OGT2115 | Preclinical (discontinued) | (131) |
| Imclone Systems (US) | Compound 7a | Preclinical (discontinued) | (138) |
| InSight Biopharmaceuticals (Israel) | Compound 4 | Preclinical (discontinued) | (139) |
| Compounds 1, 6 | (140) | ||
| Compound 2 | (141) | ||
| Compound 3 | (142) | ||
| Astra Zeneca (UK) | Antibodies | Late discovery (discontinued) | (143) |
| Endotis Pharma (France) | EP80061 from EP-8000 series | Discovery/preclinical (discontinued) | (14, 144) |
| Unknown (Shanghai Institute of Materia Medica, China) | JG3 (oligomannurarate sulfate) | Early preclinical | (145, 146) |
| RIKEN Discovery Research Institute (Japan) | RK-682 | Discovery | (147) |
| KI-105 | Discovery | (148) |